ArticleEuropean journal of microbiology & immunology2026
Evaluation of a commercial real-time PCR assay targeting Leishmania spp. with microscopically positive skin biopsies obtained from Nigerian patients.
Article in European journal of microbiology & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although real-time polymerase chain reaction (PCR) assays for leishmaniasis are considered as highly sensitive, their standardization is still ongoing. In the study presented here, the sensitivity of a commercial real-time PCR assay targeting Leishmania spp. was evaluated with Nigerian skin biopsies from patients with microscopic diagnosis of cutaneous leishmaniasis (CL). Methods: The samples were subjected to two subsequently applied types of nucleic acid extraction and afterwards characterized by two in-house real-time PCR assays targeting kinetoplast DNA (desoxyribonucleic acid) and the small subunit rRNA (ribosomal ribonucleic acid) gene of Leishmania spp. as well as by Sanger sequence analysis of the leishmanial hsp70 gene. Subsequently, the VIASURE Leishmania real-time PCR detection kit (CerTest Biotec, S.L., San Mateo de Gállego, Zaragoza, Spain) was applied with the DNA eluates. Results: From 50 bioptic samples of Nigerian patients with CL, interpretable sequences could be obtained from 30 (60%), showing best matching with Leishmania major in all instances. The VIASURE assay confirmed the abundance of leishmanial DNA in all samples after both DNA extraction schemes, showing slightly better sensitivity compared to the reference PCR assays. Conclusion: The VIASURE assay reliably detects L. major in microscopically positive bioptic samples from Nigerian CL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.